Buscar
Nuvalent Inc
NUVLAñadir a la lista de seguimiento
102.300USD
-2.110-2.02%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
8.08BCap. mercado
PérdidaP/E TTM
Más Datos de Nuvalent Inc Compañía
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Información de Nuvalent Inc
Símbolo de cotizaciónNUVL
Nombre de la empresaNuvalent Inc
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoPorter (James R)
Número de empleados142
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 29
DirecciónOne Broadway, 14Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono18573577000
Sitio Webhttps://www.nuvalent.com/
Símbolo de cotizaciónNUVL
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoPorter (James R)
Ejecutivos de Nuvalent Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Deborah Miller, J.D., Ph.D.
Dr. Deborah Miller, J.D., Ph.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Otro
46.76%
Accionistas
Accionistas
Proporción
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Otro
46.76%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
43.62%
Hedge Fund
38.79%
Investment Advisor/Hedge Fund
21.04%
Individual Investor
2.77%
Venture Capital
2.58%
Private Equity
2.26%
Research Firm
1.46%
Sovereign Wealth Fund
0.78%
Bank and Trust
0.33%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
490
86.91M
118.14%
+5.88M
2025Q4
462
75.27M
104.86%
-2.57M
2025Q3
440
73.50M
109.27%
-4.34M
2025Q2
438
75.09M
113.13%
-1.35M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Deerfield Management Company, L.P.
17.25M
23.57%
-742.57K
-4.13%
Dec 31, 2025
Fidelity Management & Research Company LLC
10.44M
14.27%
+685.62K
+7.03%
Dec 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.2%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.71M
5.06%
+578.29K
+18.49%
Dec 31, 2025
Wellington Management Company, LLP
2.46M
3.36%
+160.96K
+7.00%
Dec 31, 2025
T. Rowe Price Associates, Inc.
2.10M
2.86%
+330.62K
+18.74%
Dec 31, 2025
JP Morgan Asset Management
2.01M
2.75%
+498.40K
+32.96%
Dec 31, 2025
RA Capital Management, LP
1.88M
2.57%
+633.60K
+50.83%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Tema Oncology ETF
4.14%
ALPS Medical Breakthroughs ETF
2.65%
Global X Guru Index ETF
1.57%
State Street SPDR S&P Biotech ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
iShares Health Innovation Active ETF
0.82%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
ProShares Ultra Nasdaq Biotechnology
0.65%
Invesco Nasdaq Biotechnology ETF
0.64%
iShares Biotechnology ETF
0.39%
Ver más
Tema Oncology ETF
Proporción4.14%
ALPS Medical Breakthroughs ETF
Proporción2.65%
Global X Guru Index ETF
Proporción1.57%
State Street SPDR S&P Biotech ETF
Proporción1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.86%
iShares Health Innovation Active ETF
Proporción0.82%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.72%
ProShares Ultra Nasdaq Biotechnology
Proporción0.65%
Invesco Nasdaq Biotechnology ETF
Proporción0.64%
iShares Biotechnology ETF
Proporción0.39%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
